Literature DB >> 27251916

Neuromuscular conditions for physicians - what you need to know.

Laura Edwards1, Margaret Phillips1.   

Abstract

The Royal College of Physicians (RCP) and the British Society of Rehabilitation Medicine co-hosted a meeting entitled 'Neuromuscular conditions for physicians - what you need to know' at the RCP on 30 November 2015. There was a series of talks, ranging from in-depth genetic and molecular descriptions of pathology to multidisciplinary management of chronic neuromuscular conditions, which stimulated lively debate and discussion. Some overarching themes emerged from the day, most notably: i) the changing expectations and survival rates in Duchenne muscular dystrophy (DMD), which are transforming this disorder into an adult as much as a paediatric condition; ii) the need for integrated management and good communication -between services - whether primary, secondary and tertiary care, medical teams and intensivists, or the multiple teams involved in providing treatment to neuromuscular patients; and iii) in line with the above, the essential need for streamlining care such that patients can avoid spending most of their time attending outpatient appointments, and instead concentrate on living full lives and exploring educational, occupational, leisure and social opportunities.
© 2016 Royal College of Physicians.

Entities:  

Mesh:

Year:  2016        PMID: 27251916      PMCID: PMC5922705          DOI: 10.7861/clinmedicine.16-3-259

Source DB:  PubMed          Journal:  Clin Med (Lond)        ISSN: 1470-2118            Impact factor:   2.659


  8 in total

1.  Survival in Duchenne muscular dystrophy: improvements in life expectancy since 1967 and the impact of home nocturnal ventilation.

Authors:  Michelle Eagle; Simon V Baudouin; Colin Chandler; David R Giddings; Robert Bullock; Kate Bushby
Journal:  Neuromuscul Disord       Date:  2002-12       Impact factor: 4.296

2.  Eplerenone for early cardiomyopathy in Duchenne muscular dystrophy: a randomised, double-blind, placebo-controlled trial.

Authors:  Subha V Raman; Kan N Hor; Wojciech Mazur; Nancy J Halnon; John T Kissel; Xin He; Tam Tran; Suzanne Smart; Beth McCarthy; Michael D Taylor; John L Jefferies; Jill A Rafael-Fortney; Jeovanna Lowe; Sharon L Roble; Linda H Cripe
Journal:  Lancet Neurol       Date:  2014-12-30       Impact factor: 44.182

Review 3.  Exon skipping therapy for Duchenne muscular dystrophy.

Authors:  Ryszard Kole; Arthur M Krieg
Journal:  Adv Drug Deliv Rev       Date:  2015-05-14       Impact factor: 15.470

Review 4.  Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management.

Authors:  Katharine Bushby; Richard Finkel; David J Birnkrant; Laura E Case; Paula R Clemens; Linda Cripe; Ajay Kaul; Kathi Kinnett; Craig McDonald; Shree Pandya; James Poysky; Frederic Shapiro; Jean Tomezsko; Carolyn Constantin
Journal:  Lancet Neurol       Date:  2009-11-27       Impact factor: 44.182

Review 5.  Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care.

Authors:  Katharine Bushby; Richard Finkel; David J Birnkrant; Laura E Case; Paula R Clemens; Linda Cripe; Ajay Kaul; Kathi Kinnett; Craig McDonald; Shree Pandya; James Poysky; Frederic Shapiro; Jean Tomezsko; Carolyn Constantin
Journal:  Lancet Neurol       Date:  2009-11-27       Impact factor: 44.182

6.  Managing Duchenne muscular dystrophy--the additive effect of spinal surgery and home nocturnal ventilation in improving survival.

Authors:  Michelle Eagle; John Bourke; Robert Bullock; Mike Gibson; Jwalant Mehta; Dave Giddings; Volker Straub; Kate Bushby
Journal:  Neuromuscul Disord       Date:  2007-05-08       Impact factor: 4.296

7.  All-cause mortality and cardiovascular outcomes with prophylactic steroid therapy in Duchenne muscular dystrophy.

Authors:  Gernot Schram; Anne Fournier; Hugues Leduc; Nagib Dahdah; Johanne Therien; Michel Vanasse; Paul Khairy
Journal:  J Am Coll Cardiol       Date:  2013-01-23       Impact factor: 24.094

8.  Prevalence of genetic muscle disease in Northern England: in-depth analysis of a muscle clinic population.

Authors:  Fiona L M Norwood; Chris Harling; Patrick F Chinnery; Michelle Eagle; Kate Bushby; Volker Straub
Journal:  Brain       Date:  2009-09-18       Impact factor: 13.501

  8 in total
  1 in total

1.  Neuromuscular conditions for physicians - what you need to know.

Authors:  Andrew Frank
Journal:  Clin Med (Lond)       Date:  2016-10       Impact factor: 2.659

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.